A DNA vaccine, pCAG-HAk, expressing the full-length haemagglutinin (HA) gene of avian influenza A/Eurasian coot/Western Australia/2727/1979 (H6N2) virus, together with a Kozak sequence, in a pCAGGS vector was formulated with a novel nanoparticle, Phema. Two intramuscular immunizations of layer chickens at 3-week intervals with different doses of a nano-vaccine as well as 100µg pCAG-HAk failed to induce detectable haemagglutination-inhibition (HI) antibody. Following virus challenge, the pCAG-HAk vaccinated group did not show a statistically significant difference in frequency of virus shedding in both oropharyngeal and cloacal swabs from the naive control group. However, in comparison with the naive control group, the 100µg nano-vaccine group did significantly reduce virus shedding from the oropharynx. Despite lack of a dose-sparing effect from the nano-vaccine, there was a doseresponse effect. This pilot study indicated that Phema used as an adjuvant augmented the immune response induced by the pCAG-HAk construct.
Introduction
Genetic immunization is well documented to induce protective immunity to various infectious and non-infectious diseases in a range of animals (1) . However, rapid degradation and poor cellular uptake of plasmid DNA has significantly impacted on the efficacy of 'naked' plasmid DNA vaccines (27) . As adjuvants have historically played a major role in successful vaccine development (22) , some chemical adjuvants such as Bupivacaine (26) or Marcaine, Ubenimex (19) , monophosphoryl lipid A (MPL) (20) , QS-21 saponin (21), levamisole (11) have been explored and have showed respectable facilitating effect on immune responses to DNA vaccines. Further investigation of novel adjuvants and their formulation technologies could improve the utility of plasmid DNA vaccination.
Nano-particles, varying in size from 10 to 500 nm, are solid particles made from inert materials (2). They are potentially biocompatible and biodegradable, are relatively stable in vivo, are relatively easy to link with immunogens, have straightforward delivery methods and show little or no side effects (3, 23) . As early as 1995, solid inert beads adsorbed with antigen were reported to prime CD 8+ T cell responses (7) . Inert nanoparticles have subsequently been shown to induce strong immune responses to protein and peptide antigens in mice (8, 9) , sheep (22) , pigs (2) and cattle (2) . In the context of DNA vaccines, a cationic nanoparticle formulated plasmid DNA encoding a reporter gene enhanced in vitro cell transfection efficiency and elicited 16-200-fold greater immune responses in mice than naked plasmid DNA alone following multiple delivery routes (3, 4, 5, 6) . Co-administration of cholera toxin and lipid A with a nanoparticle-based plasmid DNA showed a synergistic effect and hence further enhanced immune responses (6) . Thus, nanoparticles, as a novel class of adjuvants, have the potential to induce immune responses to protein or plasmid DNA immunogens without the side effects typically associated with local tissue damage caused by conventional chemical adjuvants. Though the microparticle formulated plasmid DNA encoding the NP gene of A/PR/8/34 (H1N1) virus was shown to enhance immune response in mice (10) , there has been no reports on nanoparticle-based avian influenza DNA vaccines in chickens.
For Australian biosecurity reasons, a low pathogenic avian influenza (LPAI) virus, A/Eurasian coot/Western Australia/2727/1979 (H6N2), isolated from a healthy Eurasian coot (Fulica atra) in Australia, was selected to perform this DNA vaccine adjuvant study. In the present study we investigated the immunologic adjuvant effect of a novel selfprepared Phema for DNA vaccination against avian influenza.
Formulation of plasmid DNA with Phema
The pCAG-HAk plasmid DNA expressing the complete haemagglutinin (HA) gene of avian influenza A/Eurasian coot/Western Australia/2727/1979 (H6N2) virus, together with a Kozak sequence, in a pCAGGS vector was used for a DNA vaccine as described previously (24) .
A novel polymer (2-hydroxyethyl-methacrylate) (Phema), which formed a 150-300 nm hydrophilic nanoparticle suspension, was provided by the Nanotechnology Group, Murdoch University, Australia. Optimization of the solvent for mixing the Phema and DNA was determined using 100% dH 2 O, dH 2 O/ethanol (50:50) and 100% ethanol and calculation of the level of DNA binding. Then 2 mL of 1% Phema (w/v in ethanol) was sonicated for a few seconds followed by the addition of 1 mL of 1% polyvinyl alcohol (PVA) (w/v in dH 2 O) and sonication for 1 min on ice. Subsequently 200 µL of plasmid DNA (9.3 µg/µL) was added and sonicated for 2 min on ice. The resultant solution was filtered through a 0.2 µm membrane to remove the surfactant. The flow-through was centrifuged at 15,000 g for 20 min at room temperature. The pellet was dissolved in PBS and the amount of DNA coated with nano-beads was calculated by subtracting the amount of DNA in the supernatant, measured by a Nanodrop spectrophotometer (Thermo Scientific, MA, USA), from the total DNA added.
Vaccination regime
Three-week old Hy-Line chickens (free of avian influenza) were housed in free-range pens with access to water and feed ad libitum. The experimental protocol used was shown in Table 8 .1. Birds intramuscularly received two 0.2 mL injections (0.1 mL per leg) at 3 week intervals with 200 µL PBS (control), 100 µg pCAG-HAk, 10 µg, 100 µg, 200 µg Phemaadjuvanted pCAG-HAk. Sera were weekly collected to detect H6-specific antibody by haemagglutination-inhibition (HI) (16, 24) .
Three weeks following the booster vaccination, each chicken received 0.5 mL H6N2 virus (10 6.5 EID 50 /0.1 mL) by nasal instillation (0.1 mL), eyedrop (0.1 mL) and oral route (0.3 mL). Following challenge, in addition to daily observing all chickens, oropharyngeal or cloacal swabs were collected every second day over a seven day period. Virus isolation was performed as described (16).
Results and Discussion
Experiments with different ratios of alcohol and water showed that Phema adjuvant prepared with 100% ethanol as solvent gave the highest DNA binding rate. Thus, 100% alcohol was used for the preparation of the Phema adjuvant vaccine. Subsequently, the maximal plasmid DNA-Phema binding rate, determined using a constant Phema concentration and different DNA concentrations, was approximately 30%.
No H6 HI antibody titre was detected in all Hy-Line chickens following two immunizations. By 10 days post virus challenge, all birds sero-converted with significant difference in the geometric mean titre (GMT) of HI antibody between pre-and post-challenge using the paired-sample T test (Table 1) . As shown in Table 2 , in comparison with the naive control group, the pCAG-HAk vaccinated group reduced the virus excretion rate from 70.8% to 45% via oropharynx post challenge and from 12.5% to 0 via cloaca. However, the pCAGHAk vaccinated group was not significantly different from the naive control group in oropharyngeal and cloacal swabs. Possibly, the pCAG-HAk vaccine may have elicited some borderline level of protective immunity in the oropharynx (Chi square, P= 0.083).
In comparison with the naive control group, the 100µg Phema adjuvanted pCAG-HAk group showed significant decrease (Fisher's exact test, P=0.014) in virus shedding in oropharyngeal swabs but no significant difference in cloacal swabs. This suggested that Phema as adjuvant further augmented the immune response induced by the pCAG-HAk construct. For the oropharyngeal swab row, different lowercase superscript letters indicate statistical differences (P < 0.05) within the row using Chi square or Fisher's exact test. There were no significant differences between groups for the cloacal swabs.
The use of particulate carriers as novel vaccine delivery systems is an area currently receiving a high level of interest. Micro-and nano-size particle characteristics, such as size and surface properties, including surface charge and hydrophobicity, affect vaccine efficacy (28) . A range of inert nanoparticles have been tested and shown to be effective Due to the hydrophilicity of Phema, it is suspected that the ethanol solvent used in the current study may have imparted positive surface charges and allowed more absorption of the plasmid DNA than with water as a solvent. Plasmid DNA was possibly absorbed to the surface of Phema through electrostatic interaction or covalent binding and this did not appear to damage the DNA's biological functions. The interaction also appeared to be complex because the optimum effect was achieved with the 100µg dose group and the response was poorer with both the 10 and 200µg dose groups. The mechanisms behind the observed adjuvant effect have not yet been resolved. Possible mechanisms are that these nanocarriers prevent DNA degradation and facilitate targeted delivery to antigen presenting cells (12, 25) .
The pCAG-HAk vaccines with or without adjuvants did not induce a measurable antibody response in the Hy-Line chickens, however, the Phema adjuvanted pCAG-HAk vaccines gave some enhanced reduction in virus shedding from the oropharynx. The reason why the pCAG-HAk induced antibody responses in SPF chickens (24) , but lack of antibody response in Hy-Line chickens will require further investigation.
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We thank Professor Hualan Chen for allowing us to prepare the pCAG-HAk construct at the Avian Influenza Reference Laboratory at Harbin Veterinary Research Institute, China. delivery vehicles for protein and peptide antigens (3, 4, 5, 6, 12, 13, 14) . Nevertheless, application of nanoparticles with DNA vaccines is only at the exploratory stage (6, 15) . A biodegradable copolymer Phema has also been used in a drug delivery system (17, 18) . However, there appears to be no previous reports using Phema for vaccine adjuvant purposes.
